Figure 2.

Dose response of the mIFN-α pDNA treatment in the B16F10 melanoma model. Tumor growth and survival are shown for C57BL/6 mice bearing s.c. B16F10 melanoma tumors and treated with either 100 μg (a and b) or 50 μg (c and d) of mIFN-α pDNA or control pDNA. Beginning on day 4 after s.c. injection with 10⁴ B16F10 cells, mice were injected i.m. with either 100 or 50 μg of the mIFN-α pDNA or the control plasmid, twice per week, once per week, or once every other week for 6 weeks (n = 10 mice per group). Treatment of the mice with 100 μg of the mIFN-α pDNA for any of the regimens resulted in a significant reduction in tumor growth by day 19 (P < 0.005) and a significant increase in survival compared with the controls (P < 0.007). The mice receiving 50 μg of the mIFN-α pDNA once per week or twice per week also had a significant reduction in tumor growth by day 19 (P < 0.03) and a significant increase in survival (P < 0.003) compared with the controls. No significant effects on tumor growth or survival were found for the mice injected every other week with 50 μg of mIFN-α pDNA.